Genentech’s New NMOSD Drug Offers At-Home Treatment, Lower Cost

List price is below competitors from Alexion, Viela Bio

 
• By Mandy Jackson

Enspryng (satralizumab) is the third FDA-approved drug but only at-home treatment for neuromyelitis optica spectrum disorder; significant percentage of patients are not being treated.

FDA Approved
Enspryng previously was approved in Canada, Japan and Switzerland • Source: Shutterstock

More from New Products

More from Scrip